Ketorolac and metoclopramide in acute migraine headache.
- Conditions
- Acute migraine headache.Migraine
- Registration Number
- IRCT2016010425854N1
- Lead Sponsor
- Student research committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Age older than 15 and younger than 70 years; History of migraine headache with or without aura. Exclusion criteria: Age younger than 15 or older than 70 years; Duration of headache less than 4 or over 72 hours; Patients who had undergone lumbar puncturation(LP) since last 48 hours; Patients who had a systemic headache; Body temperature more than 38 degrees of Celsius; Neurologic deficit; Allergy or tolerance to drugs of study; Participated in other study; Pregnant women; If the patient within 12 hours before entering to the center, received analgesic drug; Patients who for any reason are used analgesics on a daily basis; Patients who can not communicate verbally; If the patient's lost the consciousness due to alcohol consumption and or other material is gone; People with stomach ulcers and severe digestive problems (especially chronic diarrhea); Renal failure; Liver failure; Patients who suffer simultaneously from headaches other than migraine such as tension headaches or sinusitis; If the patient is receiving anticoagulant (due to drug interactions with ketorolac); If the patient is taking probenecid (due to increasing half-life of ketorolac); If the patient receiving phenothiazines, lithium or anti epileptic drugs (due to drug interactions with metoclopramide ); If the patient prior to entering the study have akathisia.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of headache. Timepoint: A moment before the injection, 30 minutes, 60 minutes, 2 hours, 4 hours and 24 hours after the injection. Method of measurement: Visual analoge scale.;24 hours following up. Timepoint: 24 hours after the injection. Method of measurement: After 24 hours, patients are called and asked them to say the severity of their headache as this follow; severe, moderate, mild headache and without headache.
- Secondary Outcome Measures
Name Time Method Severity of vertigo( as a side effect of study medication). Timepoint: A moment before injection, 1 hours and 2 hours after injection. Method of measurement: Without vertigo, Mild to moderate vertigo but able to do activities, Sever vertigo and inability to do activities.